TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
MRK

Merck & Company Inc

Healthcare · Drug Manufacturers - General

150.90$ +0.9% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios MRK
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
56.9 762.8 145.0 22.9 23.8 14.8 13.0 12.1 11.0 14.4 33.3 100.1
4.4 4.6 5.4 5.0 4.6 3.9 3.6 3.1 3.3 4.0 4.5 4.8
6.4 7.4 8.3 7.2 6.5 5.5 4.7 4.1 4.0 5.0 6.5 7.6
4.9 5.1 5.9 5.5 4.9 4.3 4.0 3.6 3.6 4.6 5.2 5.5
23.4 44.4 41.0 16.8 16.4 10.9 9.7 9.1 8.5 10.6 18.2 26.3
19.9 30.4 30.3 24.0 19.5 14.0 13.3 13.5 16.1 21.2 21.1 19.8
5.0% 3.3% 3.3% 4.2% 5.1% 7.2% 7.5% 7.4% 6.2% 4.7% 4.7% 5.1%
Margins
72.9% 73.2% 74.4% 75.3% 75.8% 76.3% 75.7% 75.4% 75.5% 74.2% 75.9% 75.4%
13.7% 4.9% 8.0% 25.7% 22.4% 31.5% 33.1% 33.6% 38.7% 41.1% 27.6% 16.7%
7.8% 0.6% 3.8% 22.0% 19.2% 26.7% 27.2% 25.8% 29.6% 28.1% 13.6% 4.8%
22.2% 15.2% 18.0% 21.0% 23.5% 28.2% 26.6% 23.1% 20.3% 19.0% 21.5% 24.2%
Returns
11.2% 1.0% 5.7% 31.5% 27.3% 37.0% 36.1% 33.5% 36.7% 34.7% 19.5% 7.6%
4.3% 0.3% 2.2% 12.2% 10.3% 14.6% 15.1% 14.0% 14.7% 13.3% 6.9% 2.4%
Balance Sheet & Debt
26,254 28,499 25,563 26,484 23,538 24,151 26,215 27,395 23,205 35,068 43,790 47,057
2.1 4.1 2.9 1.3 1.2 0.9 1.0 1.1 0.8 1.2 2.3 3.4
38.6% 35.2% 38.1% 38.7% 37.9% 39.5% 42.0% 41.7% 40.0% 38.4% 35.7% 32.3%
0.8 0.9 0.8 0.9 0.9 0.8 0.7 0.7 0.8 0.9 1.1 1.3
Per Share
1.81 0.14 0.91 5.40 4.78 6.74 6.89 6.53 7.62 7.34 3.61 1.28
23.30 23.54 24.24 24.56 24.86 25.25 25.29 25.35 25.71 26.10 26.53 26.86
16.20 14.71 15.94 17.13 17.51 18.23 19.10 19.50 20.76 21.14 18.56 16.96
5.17 3.58 4.36 5.17 5.84 7.12 6.73 5.86 5.22 4.97 5.71 6.50

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?